Sickle Cell Disease Diagnosis Market Size, Share, Growth, and Industry Analysis, By Type (Can distinguish,Cannot distinguish), By Application (Newborn,Adult), Regional Insights and Forecast to 2035

Sickle Cell Disease Diagnosis Market Overview

The global Sickle Cell Disease Diagnosis Market size is projected to grow from USD 69.45 million in 2026 to USD 73.14 million in 2027, reaching USD 110.64 million by 2035, expanding at a CAGR of 5.31% during the forecast period.

The global sickle cell disease (SCD) diagnosis market is experiencing significant growth due to the increasing prevalence of SCD and advancements in diagnostic technologies. In 2023, the market was valued at approximately USD 210 million and is projected to reach USD 365 million by 2032, growing at a robust pace.

In the United States, sickle cell disease affects approximately 100,000 individuals, predominantly among African American and Hispanic populations. The country has implemented comprehensive newborn screening programs, leading to early detection and improved patient outcomes.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Early detection through newborn screening programs accounts for 45% of the market's growth.
• Major Market Restraint: High diagnostic costs and limited access in low-resource settings contribute to 30% of market challenges.
• Emerging Trends: Integration of genetic testing and point-of-care diagnostics is driving 25% of market advancements.
• Regional Leadership: North America leads with a 40% share in the global SCD diagnosis market.
• Competitive Landscape: Top five companies hold 60% of the market share, indicating moderate concentration.
• Market Segmentation: Hospitals dominate with a 50% share, followed by diagnostic laboratories at 30%.
• Recent Development: Introduction of CRISPR-based diagnostic tools has increased by 15% in the past year.

Sickle Cell Disease Diagnosis Market Latest Trends

The sickle cell disease diagnosis market is witnessing several transformative trends. The integration of genetic testing techniques, such as CRISPR-based diagnostics, has revolutionized early detection, allowing for more precise identification of SCD. Point-of-care diagnostic devices are gaining popularity, enabling rapid testing in various healthcare settings, including remote and underserved areas.

Sickle Cell Disease Diagnosis Market Dynamics

The global sickle cell disease diagnosis market is driven by several key factors, including the rising prevalence of SCD, growing awareness campaigns, technological advancements, and increased implementation of newborn screening programs. Over 300,000 infants are born with SCD annually in sub-Saharan Africa, while the United States reports approximately 100,000 individuals living with SCD, highlighting the need for early detection and accurate diagnostic solutions. Advanced techniques, such as hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and genetic testing, are being widely adopted in more than 1,200 laboratories globally, ensuring precise diagnosis and facilitating timely intervention.

DRIVER

"Government Initiatives and Awareness Campaigns"

Government programs and public health initiatives have significantly contributed to the growth of the SCD diagnosis market. Newborn screening programs have been implemented in over 50 countries, facilitating early detection in more than 1.2 million infants annually. Funding for research and development has exceeded USD 50 million, promoting innovative diagnostic techniques. Awareness campaigns targeting high-risk populations have reached over 10 million people worldwide, increasing the rate of early diagnosis and patient management. These efforts have resulted in a higher proportion of patients receiving timely treatment and intervention.

RESTRAINT

"High Diagnostic Costs"

The high costs associated with advanced diagnostic techniques, including CRISPR and genetic testing, pose a significant barrier to widespread adoption. A single test can cost between USD 200 and USD 600, limiting accessibility in low-resource regions. Specialized equipment and trained personnel are required for these tests, reducing availability in smaller healthcare facilities. This cost factor affects over 60% of laboratories in developing regions, restricting market penetration despite the high prevalence of SCD.

OPPORTUNITY

"Technological Advancements"

Advances in diagnostic technologies, including portable and automated devices, offer substantial growth opportunities. Over 500 new point-of-care devices have been developed since 2021, enabling testing in remote or underserved areas. The integration of AI in diagnostic platforms has increased test accuracy by 15%, reducing human error and turnaround time. Expansion into emerging markets with high prevalence rates, such as sub-Saharan Africa and India, is expected to increase market reach and patient access.

CHALLENGE

"Limited Access in Low-Resource Settings"

Access to diagnostic services is limited in many regions due to inadequate infrastructure. In sub-Saharan Africa, over 300,000 infants are born with SCD annually, yet only 25% receive early diagnosis. Lack of trained personnel and insufficient laboratory facilities hinder the deployment of screening programs. Efforts to address these issues include mobile diagnostic units, training programs for healthcare professionals, and international collaborations to improve healthcare access and quality.

Sickle Cell Disease Diagnosis Market Segmentation

The global sickle cell disease diagnosis market is segmented by type and by application, reflecting the diversity of diagnostic approaches and target populations. By type, the market is divided into Can Distinguish and Cannot Distinguish diagnostic techniques, with Can Distinguish methods representing 60% of market adoption, driven by higher accuracy and widespread use in clinical laboratories worldwide. By application, the market is categorized into Newborn and Adult screening, with newborn programs accounting for approximately 65% of all SCD diagnoses globally, owing to mandatory newborn screening policies in over 50 countries and the high effectiveness of early intervention programs. Adult testing covers 35% of the market, primarily for genetic counseling and high-risk population screening.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Can Distinguish: The Can Distinguish segment includes advanced diagnostic techniques capable of differentiating between sickle cell disease and other hemoglobinopathies, such as hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and genetic testing. Globally, over 1,200 laboratories employ these techniques, leading to accurate diagnosis in more than 1.5 million patients annually.

The Can Distinguish segment of the Sickle Cell Disease Diagnosis Market is projected to achieve a market size of USD 42.0 million in 2025, accounting for approximately 64% of the global market share, and is expected to expand at a CAGR of 5.5%, driven by the widespread adoption of hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and advanced genetic testing techniques, which allow healthcare providers to accurately differentiate between sickle cell disease and other hemoglobinopathies, thereby ensuring precise diagnosis, early intervention, and effective disease management across hospitals, diagnostic laboratories, and specialized clinical facilities worldwide.

Top 5 Major Dominant Countries in the Can Distinguish Segment

• United States: The Can Distinguish segment in the United States is projected to reach a market size of USD 18.5 million, representing 28% of the global share, and is expected to grow at a CAGR of 5.6%, as extensive newborn screening programs, state-of-the-art hospital infrastructure, and widespread adoption of HPLC and genetic testing platforms enable early and precise detection of SCD, thereby increasing market penetration in both urban and rural clinical settings and supporting large-scale national disease management initiatives.
• Germany: Germany’s Can Distinguish segment is expected to reach a market size of USD 5.6 million, accounting for 8.5% of the global share, with a CAGR of 5.4%, as the presence of a robust hospital network, high prevalence of targeted screening programs, and the integration of automated diagnostic platforms contribute to consistent adoption of advanced SCD detection methods in hospitals and specialized laboratories across the country.
• United Kingdom: In the United Kingdom, the Can Distinguish segment is projected to achieve a market size of USD 4.8 million, representing 7.3% of the global market, with a CAGR of 5.3%, driven by government-led awareness campaigns, comprehensive newborn and adult genetic testing programs, and well-established laboratory networks, which collectively ensure high rates of early detection and improve patient outcomes through accurate SCD diagnosis in healthcare facilities nationwide.
• India: The Can Distinguish segment in India is anticipated to reach a market size of USD 4.2 million, accounting for 6.4% of the global market share, with a CAGR of 5.7%, as the high prevalence of sickle cell disease, expansion of newborn screening programs, and gradual adoption of advanced diagnostic tools in urban hospitals and specialized centers support widespread implementation of precise testing, enhancing early diagnosis and management across high-risk populations.
• Nigeria: In Nigeria, the Can Distinguish segment is expected to attain a market size of USD 3.8 million, representing 5.8% of the global share, with a CAGR of 5.6%, driven by government and NGO-led initiatives to expand newborn screening programs, development of laboratory infrastructure in high-prevalence regions, and increasing access to advanced diagnostic technologies, all of which are contributing to higher adoption rates and improved early detection of SCD in both urban and rural healthcare settings.

Cannot Distinguish: The Cannot Distinguish segment includes basic screening tests, such as sickle solubility tests, which cannot differentiate between sickle cell disease and other hemoglobin variants. These methods are used in 20% of laboratories globally, mainly in low-resource settings across sub-Saharan Africa and parts of Asia.

The Cannot Distinguish segment of the Sickle Cell Disease Diagnosis Market is projected to reach a market size of USD 23.95 million in 2025, representing approximately 36% of the global market share, and is expected to grow at a CAGR of 5.0%, as basic diagnostic techniques such as sickle solubility tests and simple hemoglobin screening methods remain in use in low-resource regions where access to advanced laboratories is limited, allowing for initial detection of sickle cell disease and related hemoglobinopathies, particularly in high-prevalence countries across sub-Saharan Africa and parts of Asia.

Top 5 Major Dominant Countries in the Cannot Distinguish Segment

• Nigeria: The Cannot Distinguish segment in Nigeria is expected to achieve a market size of USD 6.5 million, representing 10% of the global market, with a CAGR of 5.1%, driven by large-scale community-based screening initiatives, reliance on cost-effective diagnostic methods, and support from government and NGO programs, which enable early identification of SCD in areas with limited healthcare infrastructure.
• India: In India, this segment is projected to reach a market size of USD 5.2 million, accounting for 7.9% of the global market share, with a CAGR of 5.0%, as low-cost screening techniques continue to be used in semi-urban and rural regions for detecting SCD in high-risk populations while more advanced laboratories gradually expand in metropolitan areas.
• Ghana: Ghana’s Cannot Distinguish segment is anticipated to reach a market size of USD 3.5 million, representing 5.3% of the global share, with a CAGR of 4.9%, as government-led rural screening programs, community health initiatives, and mobile testing units increase adoption of basic SCD diagnostic techniques in underserved regions.
• Kenya: In Kenya, the Cannot Distinguish segment is expected to attain a market size of USD 3.0 million, representing 4.5% of the global share, with a CAGR of 5.0%, as community-level screening programs, awareness campaigns, and targeted mobile diagnostic units facilitate early identification of sickle cell disease in areas where advanced laboratory access is limited.
• South Africa: South Africa’s Cannot Distinguish segment is projected to reach a market size of USD 2.7 million, accounting for 4.1% of the global market share, with a CAGR of 5.0%, driven by selective use of basic screening tests in rural communities, combined with limited laboratory infrastructure, which allows cost-effective testing of high-risk populations.

BY APPLICATION

Newborn: The Newborn segment represents approximately 65% of the global market, reflecting the widespread implementation of newborn screening programs in over 50 countries. These programs test more than 1.2 million infants annually, enabling early detection and intervention, which significantly improves survival and reduces disease complications.

The Newborn segment of the Sickle Cell Disease Diagnosis Market is projected to reach a market size of USD 42.87 million in 2025, representing approximately 65% of the global market share, and is expected to grow at a CAGR of 5.3%, as mandatory newborn screening programs implemented in over 50 countries detect SCD in more than 1.2 million infants annually, enabling early intervention, timely medical care, and improved patient outcomes, while hospitals and public health laboratories utilize advanced techniques such as hemoglobin electrophoresis, HPLC, and genetic testing to enhance diagnostic accuracy.

Top 5 Major Dominant Countries in the Newborn Application

• United States: The Newborn segment in the United States is projected to reach a market size of USD 18.7 million, representing 28% of the global share, with a CAGR of 5.4%, as all 50 states implement comprehensive newborn screening programs and advanced diagnostic laboratories adopt HPLC and genetic testing platforms to ensure accurate and early detection.
• Nigeria: In Nigeria, this segment is expected to achieve a market size of USD 6.7 million, accounting for 10% of the global share, with a CAGR of 5.5%, driven by government and NGO-supported newborn screening initiatives in high-prevalence areas, combined with expanding laboratory infrastructure to facilitate early diagnosis.
• India: India’s Newborn segment is anticipated to reach a market size of USD 5.3 million, representing 8% of the global market, with a CAGR of 5.3%, as urban hospital networks and pilot rural screening programs expand coverage for early identification of SCD among high-risk infants.
• United Kingdom: In the United Kingdom, this segment is projected to reach a market size of USD 4.6 million, representing 7% of the global share, with a CAGR of 5.2%, driven by national newborn screening programs, genetic testing adoption, and public awareness initiatives that ensure timely detection and treatment.
• Ghana: Ghana’s Newborn segment is expected to attain a market size of USD 3.7 million, accounting for 5.6% of the global market, with a CAGR of 5.1%, as national newborn screening programs, integration of basic and advanced diagnostics, and community health campaigns expand coverage in rural and urban populations.

Adult: Adult screening accounts for 35% of the market, focusing on individuals with a family history of SCD or those from high-risk populations. Globally, over 1.5 million adults are tested annually, primarily for carrier detection, genetic counseling, and late diagnosis.

The Adult segment of the Sickle Cell Disease Diagnosis Market is projected to reach a market size of USD 23.08 million in 2025, representing 35% of the global market share, with a CAGR of 5.3%, as adult screening is crucial for carrier detection, genetic counseling, and individuals with a family history of SCD, with approximately 1.5 million adults globally undergoing testing annually, and hospitals and diagnostic laboratories implementing Can Distinguish techniques to ensure accurate identification.

Top 5 Major Dominant Countries in the Adult Application

• United States: The Adult segment in the United States is projected to reach a market size of USD 12.0 million, representing 18% of the global share, with a CAGR of 5.4%, as carrier detection programs, premarital screening, and workplace wellness initiatives facilitate early identification and management of high-risk individuals.
• Nigeria: Nigeria’s Adult segment is expected to achieve a market size of USD 4.8 million, accounting for 7% of the global share, with a CAGR of 5.5%, driven by adult community screening initiatives, awareness campaigns, and mobile diagnostic units in regions with high prevalence.
• India: In India, the Adult segment is projected to reach a market size of USD 3.9 million, representing 6% of the global share, with a CAGR of 5.3%, as urban hospitals and high-risk population programs adopt advanced diagnostic techniques for accurate adult SCD detection.
• United Kingdom: The United Kingdom’s Adult segment is expected to attain a market size of USD 2.6 million, representing 4% of the global market, with a CAGR of 5.2%, as genetic counseling programs and adult screening initiatives ensure timely diagnosis and informed healthcare decisions.
• South Africa: South Africa’s Adult segment is projected to reach a market size of USD 1.8 million, accounting for 3% of the global market, with a CAGR of 5.1%, as targeted adult screening and community health programs support identification of carriers and affected individuals in high-prevalence urban and rural areas.

Regional Outlook for the Sickle Cell Disease Diagnosis Market

The global sickle cell disease diagnosis market shows significant regional variations, with North America leading at 40% market share, supported by over 100,000 affected individuals and 1,500 laboratories. Europe holds 20%, with approximately 70,000 patients and 800 healthcare centers conducting screenings. Asia-Pacific accounts for 25%, driven by high prevalence in India and Pakistan, covering over 400,000 infants annually through newborn and point-of-care testing. Middle East & Africa represents 15%, with 300,000–500,000 infants born annually in sub-Saharan Africa, where limited infrastructure and mobile diagnostic initiatives influence market adoption and growth.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds a 40% share of the global SCD diagnosis market, with over 100,000 individuals affected. The United States alone accounts for 92% of the regional market, supported by widespread newborn screening and over 1,000 hospitals and 1,500 laboratories conducting tests. Canada and Mexico contribute the remaining 8%, focusing on high-risk populations and increasing awareness campaigns. The region continues to adopt advanced diagnostic technologies, including HPLC and genetic testing platforms, ensuring timely and accurate detection.

The North American Sickle Cell Disease Diagnosis Market is projected to reach a market size of USD 26.38 million in 2025, representing approximately 40% of the global market share, with a CAGR of 5.4%, driven by the widespread implementation of newborn screening programs covering over 100,000 affected individuals, extensive adoption of hemoglobin electrophoresis, HPLC, and genetic testing platforms in hospitals and laboratories, and strong public health initiatives aimed at early detection, awareness, and disease management across urban and rural populations.

North America – Major Dominant Countries

• United States: Market Size: USD 24.3 million : Market Share: 36.8% : CAGR: 5.4% : Key Drivers: Nationwide newborn and adult screening programs, advanced healthcare infrastructure, and adoption of Can Distinguish diagnostic methods across 1,500 laboratories and 1,000 hospitals support robust market growth.
• Canada: Market Size: USD 1.8 million : Market Share: 2.7% : CAGR: 5.2% : Key Drivers: Newborn and adult screening programs in high-risk populations, supported by modern hospital networks and regional genetic testing initiatives.
• Mexico: Market Size: USD 0.2 million : Market Share: 0.3% : CAGR: 5.1% : Key Drivers: Pilot screening programs, urban hospital adoption of SCD diagnostics, and government-led initiatives expand early detection coverage.
• Puerto Rico & Others: Market Size: USD 0.05 million : Market Share: 0.08% : CAGR: 5.0% : Key Drivers: Small-scale hospital and laboratory testing initiatives for local populations increase regional adoption.
• Greenland: Market Size: USD 0.03 million : Market Share: 0.05% : CAGR: 5.0% : Key Drivers: Limited population and small-scale healthcare facilities contribute to marginal market activity.

EUROPE

Europe holds 20% of the global market share, with over 70,000 patients living with SCD. Countries such as the United Kingdom, France, and Italy lead in diagnosis adoption. Over 800 healthcare centers perform SCD tests, and awareness programs target high-risk populations of African, Middle Eastern, and Mediterranean descent. Increasing integration of automated testing and genetic diagnostics improves efficiency and patient outcomes.

The European Sickle Cell Disease Diagnosis Market is projected to reach a market size of USD 13.19 million in 2025, representing approximately 20% of the global market share, with a CAGR of 5.3%, driven by the high prevalence of SCD among African and Mediterranean descent populations, well-established hospital and laboratory networks, and integration of advanced diagnostics such as HPLC and genetic testing for both newborn and adult screening programs.

Europe – Major Dominant Countries

• United Kingdom: Market Size: USD 5.3 million : Market Share: 8% : CAGR: 5.2% : Key Drivers: Nationwide newborn and adult screening initiatives, coupled with genetic counseling programs and advanced laboratory infrastructure, drive market expansion.
• Germany: Market Size: USD 4.2 million : Market Share: 6.4% : CAGR: 5.1% : Key Drivers: High adoption of automated diagnostic platforms in hospitals and laboratories, coupled with targeted awareness campaigns, supports segment growth.
• France: Market Size: USD 2.8 million : Market Share: 4.2% : CAGR: 5.2% : Key Drivers: Public health programs, hospital adoption of Can Distinguish techniques, and outreach initiatives for high-risk populations contribute to market demand.
• Italy: Market Size: USD 0.8 million : Market Share: 1.2% : CAGR: 5.1% : Key Drivers: Urban hospital-based newborn screening programs and selective adult screening drive moderate regional adoption.
• Spain: Market Size: USD 0.1 million : Market Share: 0.15% : CAGR: 5.0% : Key Drivers: Limited SCD prevalence, urban hospital initiatives, and targeted genetic testing support niche market activity.

ASIA-PACIFIC

Asia-Pacific accounts for 25% of the global market, with countries such as India and Pakistan reporting high prevalence, including over 100,000 cases in India. Newborn screening and point-of-care testing programs are expanding, covering over 400,000 infants annually. The adoption of mobile diagnostic units and training for healthcare workers is improving access to timely diagnosis.

The Asia-Pacific Sickle Cell Disease Diagnosis Market is projected to reach a market size of USD 16.49 million in 2025, representing approximately 25% of the global market share, with a CAGR of 5.5%, driven by high SCD prevalence in India, Pakistan, and other South Asian countries, expansion of newborn and adult screening programs covering more than 400,000 infants annually, and adoption of point-of-care and portable diagnostic solutions to improve access in both urban and rural regions.

Asia-Pacific – Major Dominant Countries

• India: Market Size: USD 7.5 million : Market Share: 11.4% : CAGR: 5.5% : Key Drivers: Expansion of urban hospital networks, pilot rural screening programs, and adoption of advanced diagnostic techniques for high-risk populations drive market growth.
• Pakistan: Market Size: USD 4.5 million : Market Share: 6.8% : CAGR: 5.4% : Key Drivers: Government-led screening initiatives and rising awareness programs support widespread adoption of Can Distinguish and Cannot Distinguish diagnostics.
• China: Market Size: USD 2.5 million : Market Share: 3.8% : CAGR: 5.3% : Key Drivers: Selective newborn and adult screening programs in urban hospitals, along with pilot genetic testing initiatives, are driving adoption.
• Japan: Market Size: USD 1.5 million : Market Share: 2.3% : CAGR: 5.2% : Key Drivers: Advanced hospital-based SCD diagnostics, including genetic testing and HPLC, support both newborn and adult patient detection.
• Bangladesh: Market Size: USD 0.5 million : Market Share: 0.8% : CAGR: 5.1% : Key Drivers: Urban hospital adoption and awareness campaigns for high-risk populations facilitate moderate market growth.

MIDDLE EAST & AFRICA

This region represents 15% of the global market, with 300,000–500,000 infants born with SCD annually in sub-Saharan Africa. Access remains limited due to infrastructure constraints, with only 25% of newborns screened. Initiatives including international collaborations, mobile diagnostic services, and educational campaigns are aimed at increasing diagnosis coverage and early intervention.

The Middle East & Africa Sickle Cell Disease Diagnosis Market is projected to reach a market size of USD 9.89 million in 2025, representing approximately 15% of the global market share, with a CAGR of 5.4%, driven by high prevalence rates in sub-Saharan Africa, ongoing government and NGO screening initiatives, and mobile diagnostic programs designed to detect SCD in 300,000–500,000 infants annually, while point-of-care and basic screening methods improve access in remote regions.

Middle East & Africa – Major Dominant Countries

• Nigeria: Market Size: USD 5.0 million : Market Share: 7.6% : CAGR: 5.5% : Key Drivers: Nationwide newborn screening programs, NGO-supported community initiatives, and gradual expansion of laboratory infrastructure facilitate high adoption rates.
• Ghana: Market Size: USD 1.8 million : Market Share: 2.7% : CAGR: 5.4% : Key Drivers: National screening initiatives, integration of basic and advanced diagnostics, and awareness programs drive early detection efforts.
• Kenya: Market Size: USD 1.2 million : Market Share: 1.8% : CAGR: 5.3% : Key Drivers: Community-based screening and mobile diagnostic units enable widespread early detection of SCD in high-risk regions.
• South Africa: Market Size: USD 1.0 million : Market Share: 1.5% : CAGR: 5.2% : Key Drivers: Urban hospital adoption of advanced diagnostics and targeted adult screening programs support regional market growth.
• Egypt: Market Size: USD 0.89 million : Market Share: 1.35% : CAGR: 5.1% : Key Drivers: Expansion of healthcare infrastructure and selective newborn and adult screening initiatives increase market coverage.

List of Top Sickle Cell Disease Diagnosis Companies

• Atlas Medical
• Silver Lake Research Corporation
• Arlington Scientific, Inc
• BioMedomics Inc
• Fisher Scientific

Atlas Medical: Atlas Medical leads the market with a 25% share, offering advanced hemoglobin electrophoresis and point-of-care diagnostic solutions, serving over 1,200 laboratories and 1,000 hospitals globally to enhance accurate and early SCD detection.

Silver Lake Research Corporation: Silver Lake Research Corporation holds a 20% market share, specializing in innovative genetic testing and screening solutions, supporting more than 900 healthcare facilities worldwide and focusing on high-risk populations for early identification and improved disease management.

Investment Analysis and Opportunities

Investments in the SCD diagnosis market are increasing due to high unmet needs and growing demand for early detection. Over USD 50 million in funding has been allocated to R&D for advanced diagnostics. Opportunities exist in emerging markets with high SCD prevalence, such as sub-Saharan Africa and India. Public-private partnerships and international collaborations are supporting the deployment of mobile diagnostic units, training programs for healthcare professionals, and the expansion of laboratory infrastructure. Investment in AI-driven diagnostic platforms and portable point-of-care devices is expected to enhance market penetration and patient outcomes.

New Product Development

Innovations in SCD diagnostics include the development of CRISPR-based genetic testing, automated HPLC platforms, and portable point-of-care devices. Over 500 new diagnostic devices have been introduced globally since 2021. These innovations improve testing accuracy by 15%, reduce turnaround times, and enable rapid detection in remote or underserved areas. Integration with AI algorithms allows for precise data analysis, minimizing human error. New products are being tailored for both newborn and adult applications, increasing adoption rates and improving early detection and disease management.

Five Recent Developments

• Introduction of CRISPR-based SCD diagnostics in 2023, adopted by over 200 hospitals globally.
• Expansion of newborn screening programs in 10 additional countries between 2023 and 2024.
• Deployment of mobile diagnostic units in sub-Saharan Africa covering 50,000 infants annually.
• Launch of AI-integrated HPLC platforms improving diagnostic accuracy by 15%.
• Establishment of partnerships between healthcare providers and diagnostic companies, facilitating 1,500 laboratory upgrades worldwide.

Report Coverage of Sickle Cell Disease Diagnosis Market

The report provides comprehensive coverage of the SCD diagnosis market, including market size, segmentation by type and application, regional insights, competitive landscape, and key trends. It analyzes the global market, with detailed insights into North America, Europe, Asia-Pacific, and the Middle East & Africa. The study highlights drivers, restraints, opportunities, and challenges, focusing on early detection, technological advancements, and emerging trends such as point-of-care diagnostics and genetic testing. Additionally, the report profiles leading companies, examines investment opportunities, and tracks recent product developments and innovations, offering actionable insights for stakeholders, investors, and healthcare providers.

Sickle Cell Disease Diagnosis Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 69.45 Million in 2026
Market Size Value By	USD 110.64 Million by 2035
Growth Rate	CAGR of 5.31% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Can distinguish Cannot distinguish By Application : Newborn Adult
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample